---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-033847"
form_type: "8-K"
ticker: null
cik: "0001567892"
company_name: "Keenova Therapeutics plc"
filed_at: "2026-05-12T10:41:58+00:00"
generated_at: "2026-05-12T10:45:40.938512+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Keenova reports Q1 net sales $468M, loss $114M; reaffirms FY guidance

## Summary
- Acthar Gel net sales $170M (+47% YoY); XIAFLEX net sales $134M.
- Loss from continuing ops $114M; adjusted EBITDA $174M.
- Reaffirmed FY2026 guidance: net sales $1.94B-$2.00B, adj. EBITDA $730M-$760M.
- Realized $23M in merger synergies in Q1; on track for $100M in 2026.
- Pipeline: Phase 3 plantar fibromatosis topline expected July 2026; FDA EOP2 meeting for hammer toe June 2026.

## SEC filing metadata
- accession: 0001628280-26-033847
- form_type: 8-K
- cik: 0001567892
- company_name: Keenova Therapeutics plc
- filed_at: 2026-05-12T10:41:58+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/0001628280-26-033847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/mnk-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-033847
- JSON: https://secwatch.observer/filing/0001628280-26-033847.json
- Plain text: https://secwatch.observer/filing/0001628280-26-033847.txt

## Key facts
- Earnings Releases
  Keenova Therapeutics plc reported the first quarter ended March 31, 2026 results: revenue $468 million. Guidance reaffirmed.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $468 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Today at 8:00 a.m. ET First Quarter 2026 Highlights 3 • Acthar Gel net sales of $170 million • XIAFLEX net sales of $134 million • Net sales from continuing operations of $468 million • Loss from continuing operations of $114 million • Adjusted EBITDA from continuing operations of $174 million DUBLIN, May 12, 2026 – Keenova Therapeutics plc (“Keenova” or the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1567892/000162828026033847/0001628280-26-033847-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.